drugset
drugset / Trial / NCT00372437

A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine

NCT00372437 ↗

Phase 1/2 Completed 47 enrolled Mirati Therapeutics Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Inthis study, MGCD0103, a new anticancer drug under investigation, is given three times weekly in combination with gemcitabine to patients with solid tumours.

Timeline

Start
2006-09
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Mocetinostat Small molecule — Oral
Background Gemcitabine Small molecule 1000 mg/m2 Intravenous

Indications

neoplasm